Immunotherapy rechallenge after significant toxicity - can it be done successfully?

IF 2.7 4区医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-24 DOI:10.1080/1750743X.2025.2452838

Ashley Tan, Tara McSweeney, Nisha Sikotra, Brendan Adler, Tom van Hagen, Quentin Summers, Andrew Dean, Naomi van Hagen, Ashleigh DeMarie, Eli Gabbay, Timothy D Clay

{"title":"Immunotherapy rechallenge after significant toxicity - can it be done successfully?","authors":"Ashley Tan, Tara McSweeney, Nisha Sikotra, Brendan Adler, Tom van Hagen, Quentin Summers, Andrew Dean, Naomi van Hagen, Ashleigh DeMarie, Eli Gabbay, Timothy D Clay","doi":"10.1080/1750743X.2025.2452838","DOIUrl":null,"url":null,"abstract":"Aim: We describe a single-center burden of admissions for irAE management and rechallenge feasibility.Methods: A retrospective single-center study of patients receiving immunotherapy between 2015-2018 assessing irAE and immunotherapy rechallenge outcomes.Results: 69 of 307 patients (22%) required 124 hospitalizations for irAEs. 8 required ICU admission (2.6%). 6 (1.9%) died from irAEs. Corticosteroids were used in 96% of admissions. Additional immunosuppression was required in 26 admissions (21%). 47 of 69 patients were rechallenged (68%). The median duration between toxicity and rechallenge was 49 days (range 17-994 days). 19 of 47 rechallenged patients (40%) were admitted for subsequent irAE. 19 patients of the rechallenged group (40%) were alive at last follow-up.Conclusion: Immunotherapy rechallenge following prior irAE hospitalization is feasible but carries significant toxicity risk.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"103-111"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2452838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We describe a single-center burden of admissions for irAE management and rechallenge feasibility.

Methods: A retrospective single-center study of patients receiving immunotherapy between 2015-2018 assessing irAE and immunotherapy rechallenge outcomes.

Results: 69 of 307 patients (22%) required 124 hospitalizations for irAEs. 8 required ICU admission (2.6%). 6 (1.9%) died from irAEs. Corticosteroids were used in 96% of admissions. Additional immunosuppression was required in 26 admissions (21%). 47 of 69 patients were rechallenged (68%). The median duration between toxicity and rechallenge was 49 days (range 17-994 days). 19 of 47 rechallenged patients (40%) were admitted for subsequent irAE. 19 patients of the rechallenged group (40%) were alive at last follow-up.

Conclusion: Immunotherapy rechallenge following prior irAE hospitalization is feasible but carries significant toxicity risk.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.